🏛️ Verified NIH Record • Updated 2026-08-05

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma (NCT06891560)

Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Memorial Sloan Kettering Cancer Center

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (24 items) and avoid the listed exclusions (13 items).

Location: Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Untreated brain metastasis (subjects with treated brain metastases will be eligible, provided that they are radiographically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging \[note that the repeat imaging should be performed during study screening\], clinically stable and without requirement of steroid treatment for at least 14 days prior to the first dose of study treatment).
  • Prior malignancy if diagnosed and treated within 2 years of trial drug initiation. Patients may be included if they have completed therapy for a prior malignancy \>2 years prior to drug initiation and are currently no evidence of disease (NED). Exception: Participants with non-melanoma skin cancer or carcinoma in situ (breast DCIS, or cervical CIS) that have undergone potentially curative therapy at any time are not excluded from trial participation.
  • Prior systemic anti-cancer therapy within 4 weeks of start of study treatment.
  • ≥ Grade 2 peripheral neuropathy per CTCAE v5.0 criteria.
  • Dry eyes, keratitis, keratopathy, and active conjunctivitis.
  • New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past 6 months (baseline echocardiogram is not required unless clinically indicated).
  • Active infection, defined as any infection requiring systemic treatment
  • Subject is known to be positive for Human Immunodeficiency Virus (HIV) or active Hepatitis C Virus (HCV) or active hepatitis B (HBV) infection (positive viral load). Testing for HIV, HCV, or HBV prior to initiation of the study drug is not required. If patient's have a known history of treated HCV, then a viral load is required to confirm clearance of infection.
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Renal failure requiring active hemo- or peritoneal dialysis.
  • Breast feeding is not allowed from the start of treatment through 3 weeks after the last dose of study drug.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (7 Sites)

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey
  • Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) — Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities) — East White Plains, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York

📞 Contact the Study Coordinator

Phone: (646) 541-7062

Email: hoa@mskcc.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Adenoid Cystic Carcinoma

Explore by condition: All Adenoid Cystic Carcinoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗